摘要
目的评价FIBA（Flu、IDA FIBABu、Ara-C）方案预处理对异基因外周血干细胞移植（Allo-PBSCT）治疗急性髓细胞白血病（AML）的疗效影响。方法用Allo-PBSCT治疗AML患者48名。预处理方案为不含TBI的低剂量FIBA,采用环孢菌素＋霉酚酸酯＋甲氨蝶呤常规预防性控制移植物抗宿主病,非亲缘关系移植加用兔抗人免疫球蛋白。结果 48名患者移植后造血功能均重建,急性移植物抗宿主病发生率22.9%,慢性移植物抗宿主病发生率33.3%,其中局限型占25.4%;11名患者于移植后1-16个月分别有3名（6.25%）死于移植物抗宿主病、3名（6.25%）死于感染和5名（10.4%）死于疾病复发或进展,37名患者已无病存活3-36个月。结论 FIBA方案预处理在急性髓细胞白血病异基因外周血干细胞移植中安全可行,具有疗效可靠,植入安全,副作用小,可调控GVHD并用于预防中枢神经系统白血病等优点。
Objective To evaluate the effect of FIBA conditioning regimen for patiens with acute myeloid leukemia（AML）during allogeneic hematopoitic stem cell transplantation.Methods A total of 48 patients with AML underwent allo-PBSCT pretreated by conditioning regimens with reduced intensity of FIBA（including FLU,IDA,Bu,Ara-C）.Cyclosporine A（CsA）,mycophenolate mofetil（MMF）,methotrexate（MTX）and additional ATG were adopted to prevent graft-versus-host disease（GVHD）during unrelated-donor PBSCT.Results All patients obtained hematopoieteic reconstitution.The incidence rate of acute GVHD was 22.9%,and chronic GVHD was 33.3%,among which the limited were 25.4%.And 11 patients died of GVHD,infection,disease relapse or development,and 37 patients were disease-free survival（DFS）from 3 to 36 months.Conclusion FIBA conditioning regimen for patients with AML during allo-PBSCT is safe,effective and feasible,which can be used to regulate GVHD and prevent CNS leukemia with minor side effect.
出处
《中国输血杂志》
CAS
CSCD
北大核心
2011年第1期15-18,共4页
Chinese Journal of Blood Transfusion
基金
国家自然科学基金(810703888)
重庆市自然科学基金重点课题(2009BA5056)
第三军医大学临床科研课题(2010D249)
关键词
急性髓系白血病
预处理
外周血造血干细胞移植
异基因
Acute myeloid leukemia（AML）
Pretreatment
Peripheral blood stem cell transplantation
Allogenetic
